JP2017518360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518360A5 JP2017518360A5 JP2017505735A JP2017505735A JP2017518360A5 JP 2017518360 A5 JP2017518360 A5 JP 2017518360A5 JP 2017505735 A JP2017505735 A JP 2017505735A JP 2017505735 A JP2017505735 A JP 2017505735A JP 2017518360 A5 JP2017518360 A5 JP 2017518360A5
- Authority
- JP
- Japan
- Prior art keywords
- substituents
- heterocyclic group
- membered
- optionally
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 39
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 7
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 206010029113 Neovascularisation Diseases 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims 3
- 231100000673 dose–response relationship Toxicity 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 230000003018 neuroregenerative effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1406956.1A GB201406956D0 (en) | 2014-04-17 | 2014-04-17 | Compounds |
| GB1406956.1 | 2014-04-17 | ||
| PCT/GB2015/051172 WO2015159103A1 (en) | 2014-04-17 | 2015-04-17 | Piperazine derivatives for treating disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518360A JP2017518360A (ja) | 2017-07-06 |
| JP2017518360A5 true JP2017518360A5 (enExample) | 2018-06-07 |
| JP6579714B2 JP6579714B2 (ja) | 2019-09-25 |
Family
ID=50928932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505735A Active JP6579714B2 (ja) | 2014-04-17 | 2015-04-17 | 化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9695160B2 (enExample) |
| EP (1) | EP3131886B1 (enExample) |
| JP (1) | JP6579714B2 (enExample) |
| CN (1) | CN107001344B (enExample) |
| AU (1) | AU2015248656B2 (enExample) |
| ES (1) | ES2836105T3 (enExample) |
| GB (1) | GB201406956D0 (enExample) |
| WO (1) | WO2015159103A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104869990B (zh) * | 2012-10-17 | 2022-12-20 | 艾科耐特有限公司 | 用于治疗眼部新生血管形成的化合物 |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
| CN110520127B (zh) | 2017-03-26 | 2023-05-16 | 武田药品工业株式会社 | 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺 |
| CA3077749A1 (en) | 2017-09-27 | 2019-04-04 | Exonate Limited | Srpk1 inhibitors |
| CN108912116A (zh) * | 2018-08-15 | 2018-11-30 | 翟学旭 | 一种含氮杂环类衍生物及其在视网膜疾病中的应用 |
| WO2021148420A1 (en) * | 2020-01-22 | 2021-07-29 | F. Hoffmann-La Roche Ag | Novel heterocyclic compounds |
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| EP4370514A1 (en) | 2021-07-15 | 2024-05-22 | F. Hoffmann-La Roche AG | Imidazole derivatives and their use as antibiotics |
| CN120917015A (zh) * | 2023-01-20 | 2025-11-07 | 元启(苏州)生物制药有限公司 | Srpk1抑制剂和使用方法 |
| CN116898971B (zh) * | 2023-07-17 | 2024-11-22 | 武汉大学人民医院（湖北省人民医院） | Srpk3基因在制备治疗心肌肥厚的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2840314B1 (fr) | 2002-06-03 | 2004-08-20 | Inst Francais Du Petrole | Methode d'isolation thermique, procede de preparation d'un gel isolant et gel isolant obtenu |
| DK2666481T3 (en) | 2003-12-26 | 2019-02-25 | Masatoshi Hagiwara | A method for regulating the phosphorylation of SR protein and antiviral agents comprising an SR protein activity regulator as the active ingredient |
| EP2078003B1 (en) * | 2006-10-31 | 2017-03-08 | Merck Sharp & Dohme Corp. | Anilinopiperazine derivatives and methods of use thereof |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| EP2358382A2 (en) | 2008-11-22 | 2011-08-24 | The University of Bristol | NOVEL USES OF VEGFxxxB |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| CN104869990B (zh) * | 2012-10-17 | 2022-12-20 | 艾科耐特有限公司 | 用于治疗眼部新生血管形成的化合物 |
-
2014
- 2014-04-17 GB GBGB1406956.1A patent/GB201406956D0/en not_active Ceased
-
2015
- 2015-04-17 AU AU2015248656A patent/AU2015248656B2/en active Active
- 2015-04-17 JP JP2017505735A patent/JP6579714B2/ja active Active
- 2015-04-17 WO PCT/GB2015/051172 patent/WO2015159103A1/en not_active Ceased
- 2015-04-17 EP EP15718262.7A patent/EP3131886B1/en active Active
- 2015-04-17 CN CN201580031650.5A patent/CN107001344B/zh active Active
- 2015-04-17 ES ES15718262T patent/ES2836105T3/es active Active
- 2015-04-17 US US15/304,678 patent/US9695160B2/en active Active
-
2017
- 2017-05-31 US US15/609,596 patent/US9796707B2/en active Active
- 2017-09-19 US US15/708,315 patent/US9932330B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220105A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2021002428A (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas. | |
| SA520411843B1 (ar) | Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2013512903A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| NZ708593A (en) | Novel pyrazole derivative | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| JP2019500387A5 (enExample) | ||
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR095371A1 (es) | Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos | |
| JP2015511609A5 (enExample) | ||
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| JP2019535723A5 (enExample) | ||
| JP2020500866A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| BR112015024472A2 (pt) | derivados de quinolina multifuncionais como agentes anti-neurodegenerativos |